B. Riley Reiterates Buy Rating for Jazz Pharmaceuticals (JAZZ)

B. Riley restated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note issued to investors on Tuesday. They currently have a $206.00 price target on the specialty pharmaceutical company’s stock.

Several other brokerages have also recently issued reports on JAZZ. FBR & Co initiated coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a buy rating and a $206.00 target price on the stock. Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $210.00 to $195.00 and set an outperform rating on the stock in a research note on Wednesday, November 8th. Leerink Swann initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, January 2nd. They set an outperform rating and a $180.00 target price on the stock. Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 28th. They set a neutral rating and a $165.00 target price on the stock. Finally, UBS Group reaffirmed a buy rating and set a $172.00 target price (down previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $179.44.

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) traded down $0.55 on Tuesday, reaching $148.70. 417,379 shares of the company’s stock traded hands, compared to its average volume of 465,585. Jazz Pharmaceuticals has a 52 week low of $117.16 and a 52 week high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. The firm has a market cap of $8,950.00, a PE ratio of 24.50, a PEG ratio of 0.80 and a beta of 0.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.40. Jazz Pharmaceuticals had a net margin of 23.58% and a return on equity of 22.92%. sell-side analysts predict that Jazz Pharmaceuticals will post 9.76 EPS for the current year.

In other news, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $152.16, for a total transaction of $106,512.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Patrick G. Enright sold 352 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the transaction, the director now owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,452 shares of company stock worth $2,985,885. Insiders own 4.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC raised its holdings in Jazz Pharmaceuticals by 11.4% in the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares during the period. Vanguard Group Inc. raised its holdings in Jazz Pharmaceuticals by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after buying an additional 153,908 shares during the period. Bank of New York Mellon Corp raised its holdings in Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,486,426 shares of the specialty pharmaceutical company’s stock valued at $217,390,000 after buying an additional 105,838 shares during the period. Westfield Capital Management Co. LP raised its holdings in Jazz Pharmaceuticals by 8.7% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,438,481 shares of the specialty pharmaceutical company’s stock valued at $210,378,000 after buying an additional 115,217 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Jazz Pharmaceuticals by 3.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,201,500 shares of the specialty pharmaceutical company’s stock valued at $186,833,000 after buying an additional 40,537 shares during the period. Hedge funds and other institutional investors own 91.26% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3147760/b-riley-reiterates-buy-rating-for-jazz-pharmaceuticals-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.